Initial Tests Show Arthritis Drug Does Not Treat COVID-19October 28, 2020
Results of the initial tests of anti-inflammatory drug, Tocilizumab, do not look promising.
Tocilizumab is a treatment for rheumatoid arthritis and to manage the dangerous side effect of a certain cancer treatment. Thus, the drug became a candidate drug to help COVID-19 patients facing excessive inflammation. Tocilizumab blocks the activity of interleukin 6, which contributes to the immune system's inflammatory response. High amounts of the pro-inflammatory protein have been found in COVID-19 patients who had severe symptoms.
Only one out of the four clinical trials passed the mark in evaluating the efficacy of the drug. The only study that concluded that the drug was helpful had a weaker design compared to the others.
Read more details in Science News.
You might also like:
- Study: Heartburn Medicine Doesn't Work as COVID-19 Antiviral
- Researchers Engineer Drug-Like Compounds that Disable SARS-CoV-2's Replication Engine
- Pocket K No. 58: COVID-19 Treatment Efforts Using Plant Technologies
Biotech Updates is a weekly newsletter of ISAAA, a not-for-profit organization. It is distributed for free to over 22,000 subscribers worldwide to inform them about the key developments in biosciences, especially in biotechnology. Your support will help us in our mission to feed the world with knowledge. You can help by donating as little as $10.
See more articles:
News from Around the World
- International Regulators, Tech Developers Share Experiences on Animal Biotech
- Ghana's Scientists to Seek Commercial Approval for GE Cowpea
- Thai Farmer Highlights Role of Biotech in Changing the Course of Agriculture
- UAE Passes Mandatory Biotech Labeling Law
- Scientists Find Gene for Slim Inflorescence Shape of Barley
- Research Team Finds Hormones Control Root Length
- Higher Income Nations See Harm in GM Food; Lower Income Countries Think they Help People
- Scientists Uncover Molecular Mechanisms in Drought Sensitivity of Rice
- Comprehensive Advancement in Plant Virus Resistance Due to Genetic Engineering
- Genome Editing Offers Solutions to GHG Emission Problems
- Initial Tests Show Arthritis Drug Does Not Treat COVID-19
- SARS-CoV-2 Uses Neuropilin-1 to Infect Human Cells
Read the latest:
- Biotech Updates (November 29, 2023)
- Gene Editing Supplement (November 29, 2023)
- Gene Drive Supplement (February 22, 2023)
Subscribe to BU: